Navidea Biopharmaceuticals announced results from two Phase 3 clinical trials of Lymphoseek (technetium 99m tilmanocept) Injection in patients with melanoma of the skin, assessing the performance of ...

Navidea announced the launch of Lymphoseek (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer ...

Dysadherin Overexpression in Pancreatic Ductal Adenocarcinoma Reflects Tumor Aggressiveness: Relationship to E-Cadherin Expression Purpose: Sensitive detection methods and accurate reporting are ...

September 11, 2012 — Approval of technetium (99m Tc)-tilmanocept for injection (Lymphoseek, Navidea), a product developed for intraoperative lymphatic mapping (ILM) in breast cancer and melanoma ...

A green fluorescent dye beat the standard blue dye for mapping lymph nodes when the two were compared directly in women with uterine or cervical cancers. The finding comes from a phase 3 ...

Navidea Biopharmaceuticals ($NAVB) overcame an initial FDA rejection 6 months ago and finally obtained approval for Lymphoseek, a new radioactive diagnostic imaging ...

The US Food and Drug Administration (FDA) has approved Navidea Biopharmaceuticals' Lymphoseek (technetium Tc 99m tilmanocept) Injection, a novel product indicated for use in lymphatic mapping ...

BIDMC's cancer experts use sentinel node study to accurately pinpoint and remove lymph nodes affected by cancer. Learn more.

Studies in breast cancer, melanoma, colon cancer, lung cancer and almost all solid malignancies that spread to lymph nodes have confirmed that metastatic cells move in an orderly manner from the ...

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has entered into an agreement to collaborate with Maimonides Medical Centre to ...

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and ...